PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study
Standard
PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study. / Weber, Manuel; Kurek, Claudia Ewa; Barbato, Francesco; Eiber, Matthias; Maurer, Tobias; Nader, Michael; Hadaschik, Boris; Grünwald, Viktor; Herrmann, Ken; Wetter, Axel; Fendler, Wolfgang Peter.
In: J NUCL MED, Vol. 62, No. 1, 01.2021, p. 88-91.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study
AU - Weber, Manuel
AU - Kurek, Claudia Ewa
AU - Barbato, Francesco
AU - Eiber, Matthias
AU - Maurer, Tobias
AU - Nader, Michael
AU - Hadaschik, Boris
AU - Grünwald, Viktor
AU - Herrmann, Ken
AU - Wetter, Axel
AU - Fendler, Wolfgang Peter
N1 - © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2021/1
Y1 - 2021/1
N2 - The low detection rate of conventional imaging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of castration-resistant prostate cancer (CRPC). We thus assessed the value of prostate-specific membrane antigen (PSMA) PET/CT in the detection of early CRPC (prostate-specific antigen ≤ 3 ng/mL). Methods: We identified 55 patients with early CRPC from our institutional database. PSMA PET/CT and its CT component were interpreted independently by 3 masked readers. The primary endpoint was the per-patient detection rate; secondary endpoints were interobserver agreement and predictors of PET positivity. Results: PSMA PET/CT was positive in 41 of 55 (75%) patients. Sixteen of 55 (29%) patients had local disease only, and 25 of 55 (45%) had M1 disease. Overall, PSMA PET/CT interobserver agreement was substantial by Landis and Koch criteria (Fleiss κ = 0.77). Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3.
AB - The low detection rate of conventional imaging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of castration-resistant prostate cancer (CRPC). We thus assessed the value of prostate-specific membrane antigen (PSMA) PET/CT in the detection of early CRPC (prostate-specific antigen ≤ 3 ng/mL). Methods: We identified 55 patients with early CRPC from our institutional database. PSMA PET/CT and its CT component were interpreted independently by 3 masked readers. The primary endpoint was the per-patient detection rate; secondary endpoints were interobserver agreement and predictors of PET positivity. Results: PSMA PET/CT was positive in 41 of 55 (75%) patients. Sixteen of 55 (29%) patients had local disease only, and 25 of 55 (45%) had M1 disease. Overall, PSMA PET/CT interobserver agreement was substantial by Landis and Koch criteria (Fleiss κ = 0.77). Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3.
U2 - 10.2967/jnumed.120.245456
DO - 10.2967/jnumed.120.245456
M3 - SCORING: Journal article
C2 - 32444377
VL - 62
SP - 88
EP - 91
JO - J NUCL MED
JF - J NUCL MED
SN - 0161-5505
IS - 1
ER -
